Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III
Prostatitis
About this trial
This is an interventional treatment trial for Prostatitis focused on measuring Prostatitis
Eligibility Criteria
Inclusion Criteria: Diagnosis of male Chronic Pelvic Pain Syndrome Type III Age 18 - 65 Pelvic pain duration of at least 3 months Exclusion Criteria: Urinary tract infection within the last year Sexually transmitted disease within 3 months Antiviral therapy or antibiotics within the last 3 months Currently taking any medications or recreational drugs containing nitrates 3A4 inhibitors such as erythromycin, ketoconazole, or itraconazole Alpha-blocker therapy for treatment of high blood pressure or prostate problems Suffered a heart attack, stroke or life-threatening arrhythmia within the last months Cardiac failure or coronary artery disease causing unstable angina Resting hypotension (BP<90/50) or hypertension (BP>170/110) Patients with retinitis pigmentosa Kidney, liver or blood problems (including sickle cell anemia or leukemia) Allergy to sildenafil Deformed penis, Peyronie's disease or ever having had an erection lasting more than 4 hours Stomach ulcers or any types of bleeding problems Use of any other medical treatments that cause erections: pills, medicines that are injected or inserted into the penis, implants or vacuum pumps Back pain, unilateral testicular pain or rectal pain only Post-surgical pain Prostate biopsy or cystoscopy within 3 months Pain from another source in the genital tract, such as kidney stones or neoplasm History of prostate, bladder, renal or other urinary malignancies History of intravesical Bacillus Calmette-Guerin (BCG) Ulcerative colitis or Crohn's disease Radiation therapy to pelvis History of genitourinary tuberculosis Any neurological abnormalities including spinal cord injury and stroke Overtly psychotic or suicidal Unable to understand the protocol In addition, subjects will be asked to refrain from having any new treatment for prostatitis during the study period, but will be allowed to remain on stable chronic therapy that they have been receiving for 3 or more months
Sites / Locations
- University of Washington, Urology Clinic